Wahyu Dwi Anggoro
IDXChannel - PT Kalbe Farma Tbk or Kable (KLBF) is targeting sales growth of 10 to 15 percent in 2023 or around Rp33 trillion. To support the company’s business plan, Kalbe will allocate capital expenditure of Rp1 trillion.
As of September 2022, kalbe farma posted net sales of Rp21.18 trillion, up 10.9 percent year on year. Meanwhile, the company’s net profit reached Rp2.28 trillion, an increase of 8.6 percent.
To achieve the company’s target, Kalbe Farma focuses on developing biological-based products, such as monoclonal antibodies with the trademark rituxikal. This is due to low market penetration of biological-based drug products. In fact, the demand in Indonesia is quite high.
Furthermore, Kalbe’smanagement explained, imported biological-based drug products are sold at relatively high prices so that the Indonesian government hopes to be able to produce these products domestically.
To support the 2023 target, kalbe Farma plans to allocate a minimum capital expenditure of iRp1 trillion in 2023. previously, the pharmaceutical company budgeted the same amount for 2022.
